Photo Credit: David Frabotta, executive editor
Solriamfetol is approved for adult patients suffering from the effects of narcolepsy and OSA.
New guide details actions for pharmacists and payers.
CHPA says over $146 billion and countless productivity hours are saved by the availability and accessibility of OTC medications and products.
Aggregated data highlights manufacturers responsible for price increases.
Indicated for breast cancer, and gastric or gastroesophageal junction adenocarcinoma.
Only new biosimilars and interchangeables will recieve four-letter suffixes.
Restricted implants indicated for maintenance of opioid dependency.
The new device will increase real-time personalization and predictive diagnostics for patients.